{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T01:04:18Z","timestamp":1795223058922,"version":"4.10.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatocellular carcinoma (HCC) is a cancer with high incidence and mortality rate. Although immune checkpoint inhibitors (ICIs) improved survival outcomes for HCC patients, limited objective response rate highlights the urgency of investigating determinants of immunotherapy. Here, we explore HCC resistance mechanisms following neoadjuvant \u03b1PD-1 immunotherapy by constructing a comprehensive multi-modal single-cell transcriptomic atlas consisting of 14 HCC patients treated with \u03b1PD-1 from our cohort (ClinicalTrials.gov ID: NCT06571396) and 60 external HCC cases with heterogeneous treatment backgrounds. Supervised by clinical outcomes of our cohort, we identify positive and negative regulators of immunotherapy within the tumor immune microenvironment (TIME), especially lipid-associated macrophages (LAM) with increased lipid metabolic state in non-responders and characterized by\n                    <jats:italic>C1QA<\/jats:italic>\n                    ,\n                    <jats:italic>FABP1<\/jats:italic>\n                    , and\n                    <jats:italic>APOA1<\/jats:italic>\n                    expression. We further show the presence, exogenous inducements and immunosuppressive functions of LAM, along with regulation strategies of its lipid-associated condition, including lycopene and chiglitazar. Furthermore, we construct interaction networks of immune regulators across responders and non-responders, showing distinct ligand-receptor landscapes with intervention targets. We reveal the TIME components including immunosuppressive LAMs that influence immunotherapy outcomes, thus providing evidence and insights for exploring immune landscape and therapeutic strategies for HCC immunotherapy. ClinicalTrials.gov ID: NCT06571396\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-75949-y","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:41Z","timestamp":1785521081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated single-cell multi-omics characterization reveals lipid-associated macrophage-mediated immunosuppression in neoadjuvant immunotherapy of hepatocellular carcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Shengxuan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2108-3608","authenticated-orcid":false,"given":"Qiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisen","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6056-2097","authenticated-orcid":false,"given":"Zhaoru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-5981","authenticated-orcid":false,"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5108-1774","authenticated-orcid":false,"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"75949_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"75949_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2015.07.018","volume":"379","author":"L Li","year":"2016","unstructured":"Li, L. & Wang, H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 379, 191\u2013197 (2016).","journal-title":"Cancer Lett."},{"key":"75949_CR3","doi-asserted-by":"crossref","unstructured":"Gabbia, D. & De Martin, S. Insights into hepatocellular carcinoma: from pathophysiology to novel therapies. Int. J. Mol. Sci. 25, 4188 (2024).","DOI":"10.3390\/ijms25084188"},{"key":"75949_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med"},{"key":"75949_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 402, 1133\u20131146 (2023).","journal-title":"Lancet"},{"key":"75949_CR6","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"75949_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","volume":"35","author":"I Melero","year":"2024","unstructured":"Melero, I. et al. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. Ann. Oncol. 35, 537\u2013548 (2024).","journal-title":"Ann. Oncol."},{"key":"75949_CR8","first-page":"298","volume":"12","author":"QF Chen","year":"2024","unstructured":"Chen, Q. F., Chen, S., Chen, M., Lyu, N. & Zhao, M. Improving the conversion success rate of hepatocellular carcinoma: focus on the use of combination therapy with a high objective response rate. J. Clin. Transl. Hepatol. 12, 298\u2013304 (2024).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"75949_CR9","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 9, 1651\u20131659 (2023).","journal-title":"JAMA Oncol."},{"key":"75949_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"HD Kim","year":"2024","unstructured":"Kim, H. D. et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat. Med 30, 699\u2013707 (2024).","journal-title":"Nat. Med"},{"key":"75949_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ccell.2025.01.001","volume":"43","author":"X Guo","year":"2025","unstructured":"Guo, X. et al. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. Cancer Cell 43, 248\u2013268.e249 (2025).","journal-title":"Cancer Cell"},{"key":"75949_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue, R. et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612, 141\u2013147 (2022).","journal-title":"Nature"},{"key":"75949_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng, Y. et al. Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma. Cell Discov. 11, 1 (2025).","journal-title":"Cell Discov."},{"key":"75949_CR14","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen, A. et al. Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389\u20131399 (2023).","journal-title":"Nat. Med."},{"key":"75949_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04716-0","volume":"21","author":"J Huang","year":"2023","unstructured":"Huang, J., Wu, Q., Geller, D. A. & Yan, Y. Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC). J. Transl. Med. 21, 815 (2023).","journal-title":"J. Transl. Med."},{"key":"75949_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02314-w","volume":"24","author":"F Zeng","year":"2025","unstructured":"Zeng, F. et al. Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response. Mol. Cancer 24, 110 (2025).","journal-title":"Mol. Cancer"},{"key":"75949_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803037","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Macrophage polarization and its role in liver disease. Front. Immunol. 12, 803037 (2021).","journal-title":"Front. Immunol."},{"key":"75949_CR18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s43018-024-00824-y","volume":"5","author":"X Qiu","year":"2024","unstructured":"Qiu, X. et al. Spatial single-cell protein landscape reveals vimentin(high) macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma. Nat. Cancer 5, 1557\u20131578 (2024).","journal-title":"Nat. Cancer"},{"key":"75949_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32283-3","volume":"13","author":"Y Lu","year":"2022","unstructured":"Lu, Y. et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat. Commun. 13, 4594 (2022).","journal-title":"Nat. Commun."},{"key":"75949_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13046-025-03287-w","volume":"44","author":"H Guo","year":"2025","unstructured":"Guo, H. et al. TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 44, 20 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"75949_CR21","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.7150\/thno.95971","volume":"14","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma. Theranostics 14, 3526\u20133547 (2024).","journal-title":"Theranostics"},{"key":"75949_CR22","doi-asserted-by":"crossref","unstructured":"Wang, H. et al. POSTN(+) cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma. J. Immunother. Cancer 12, e008721 (2024).","DOI":"10.1136\/jitc-2023-008721"},{"key":"75949_CR23","unstructured":"Cappuyns, S. et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. J. Hepatol. 82, 1036\u20131049 (2024)."},{"key":"75949_CR24","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","volume":"75","author":"L Ma","year":"2021","unstructured":"Ma, L. et al. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Hepatol. 75, 1397\u20131408 (2021).","journal-title":"J. Hepatol."},{"key":"75949_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","volume":"183","author":"A Sharma","year":"2020","unstructured":"Sharma, A. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 183, 377\u2013394.e321 (2020).","journal-title":"Cell"},{"key":"75949_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35291-5","volume":"13","author":"L Ma","year":"2022","unstructured":"Ma, L. et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat. Commun. 13, 7533 (2022).","journal-title":"Nat. Commun."},{"key":"75949_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41421-023-00529-z","volume":"9","author":"GQ Zhu","year":"2023","unstructured":"Zhu, G. Q. et al. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 9, 25 (2023).","journal-title":"Cell Discov."},{"key":"75949_CR28","first-page":"779","volume":"14","author":"J Zhou","year":"2025","unstructured":"Zhou, J. et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 Edition). Liver Cancer 14, 779\u2013835 (2025).","journal-title":"Liver Cancer"},{"key":"75949_CR29","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","volume":"25","author":"A D\u2019Alessio","year":"2024","unstructured":"D\u2019Alessio, A. et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 25, 1465\u20131475 (2024).","journal-title":"Lancet Oncol."},{"key":"75949_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"75949_CR31","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"75949_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2159-8290.CD-21-0316","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 12, 134\u2013153 (2022).","journal-title":"Cancer Discov."},{"key":"75949_CR33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J. Hepatol. 78, 770\u2013782 (2023).","journal-title":"J. Hepatol."},{"key":"75949_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381\u2013386 (2014).","journal-title":"Nat. Biotechnol."},{"key":"75949_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao, J. et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496\u2013502 (2019).","journal-title":"Nature"},{"key":"75949_CR36","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1093\/nar\/gkab638","volume":"49","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. CellCall: integrating paired ligand-receptor and transcription factor activities for cell-cell communication. Nucleic Acids Res. 49, 8520\u20138534 (2021).","journal-title":"Nucleic Acids Res."},{"key":"75949_CR37","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"key":"75949_CR38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2024.09.029","volume":"82","author":"X Yang","year":"2025","unstructured":"Yang, X. et al. FABP5(+) lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity. J. Hepatol. 82, 676\u2013689 (2025).","journal-title":"J. Hepatol."},{"key":"75949_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400185","volume":"11","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. Patient-derived tumor organoids combined with function-associated ScRNA-seq for dissecting the local immune response of lung cancer. Adv. Sci. 11, e2400185 (2024).","journal-title":"Adv. Sci."},{"key":"75949_CR40","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1093\/nar\/gkab1201","volume":"50","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids. Nucleic Acids Res. 50, e28 (2022).","journal-title":"Nucleic Acids Res."},{"key":"75949_CR41","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.21037\/tcr-24-93","volume":"13","author":"W Zhao","year":"2024","unstructured":"Zhao, W. et al. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience. Transl. Cancer Res. 13, 2315\u20132331 (2024).","journal-title":"Transl. Cancer Res."},{"key":"75949_CR42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s11845-022-03131-6","volume":"192","author":"C Zhu","year":"2023","unstructured":"Zhu, C., Dai, B., Zhan, H. & Deng, R. Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients. Ir. J. Med. Sci. 192, 1065\u20131071 (2023).","journal-title":"Ir. J. Med. Sci."},{"key":"75949_CR43","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma. J. Immunother. Cancer 13, e013516 (2025).","DOI":"10.1136\/jitc-2025-013516"},{"key":"75949_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450\u2013456 (2021).","journal-title":"Nature"},{"key":"75949_CR45","first-page":"223","volume":"14","author":"X Bi","year":"2025","unstructured":"Bi, X. et al. Consensus of Chinese experts on neoadjuvant and conversion therapies for hepatocellular carcinoma: 2023 update. Liver Cancer 14, 223\u2013238 (2025).","journal-title":"Liver Cancer"},{"key":"75949_CR46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"75949_CR47","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"75949_CR48","doi-asserted-by":"crossref","unstructured":"Kotliar, D. et al. Identifying gene expression programs of cell-type identity and cellular activity with single-cell RNA-Seq. Elife 8, 43803 (2019).","DOI":"10.7554\/eLife.43803"},{"key":"75949_CR49","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"},{"key":"75949_CR50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nmeth.4150","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Single-cell mRNA quantification and differential analysis with Census. Nat. Methods 14, 309\u2013315 (2017).","journal-title":"Nat. Methods"},{"key":"75949_CR51","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/s41556-025-01801-y","volume":"27","author":"E Ibrahimi","year":"2025","unstructured":"Ibrahimi, E. & Wolford, B. N. Ten essential tips for robust statistics in cell biology. Nat. Cell Biol. 27, 1884\u20131886 (2025).","journal-title":"Nat. Cell Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75949-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75949-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75949-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:36:09Z","timestamp":1788302169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75949-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75949"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75949-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9381"}}